Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia.
Ontology highlight
ABSTRACT: Phosphatidylinositol-3-kinase (PI3K) pathway hyperactivation has been associated with the development of cancer and treatment resistance. PI3K inhibitors are now used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer. Hyperglycemia, a frequently observed adverse event with PI3K inhibitors (PI3Ki), is regarded as an on-target effect because inhibition of the PI3K pathway has been shown to decrease glucose transport and increase glycogenolysis and gluconeogenesis. PI3Ki-induced hyperglycemia results in a compensatory increase in insulin release, which has been shown to reduce the efficacy of treatment by reactivating the PI3K pathway in preclinical models. Patients with an absolute or relative def
SUBMITTER: Goncalves MD
PROVIDER: S-EPMC8793384 | biostudies-literature | 2022 Jan-Dec
REPOSITORIES: biostudies-literature
ACCESS DATA